Scribd Logo
Upload

Welcome to Scribd!

  • 183 views

    Citilin® (Amp) : Korea United Pharm Pharma 3 Nootropics & Neurotonics

    Uploaded by

    dipenhydramine

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOCX, PDF, TXT or read online from Scribd

    Citilin® (Amp) : Korea United Pharm Pharma 3 Nootropics & Neurotonics

    Uploaded by

    dipenhydramine
    183 views6 pages

    Original Title

    Citilin

    Copyright

    © Attribution Non-Commercial (BY-NC)

    Available Formats

    DOCX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    183 views6 pages

    Citilin® (Amp) : Korea United Pharm Pharma 3 Nootropics & Neurotonics

    Uploaded by

    dipenhydramine

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    You are on page 1of 6

    Citilin® [amp]

    Korea United Pharm [ Pharma 3 ]


    MIMS Class : Nootropics & Neurotonics

    See related Citilin amp information


    Contents Citicoline
    Indications Treatment of stupor caused by head trauma, cerebral surgery, acute stage
    of cerebral infarction and hemiplegia after cerebral apoplexy. Treatment
    of Parkinson's disease in combination w/ anticholinergics.

    Concomitant therapy w/ antiproteolytic agents for pancreatitis.


    Dosage Stupor Caused by Head Trauma and Cerebral Surgery: The usual
    adult dosage of citicoline is 100-500 mg once or twice daily given in
    divided IV or IM administration.

    Stupor Caused by Acute Stage Infarction: Usual adult dosage of


    citicoline is 1 g once daily for 2 consecutive weeks.

    Hemiplegia After Cerebral Apoplexy: Citicoline 1 g or 250 mg is


    administered IV once a day for 4 weeks> If symptoms are improved,
    administer IV for 4 more weeks.

    Parkinson's Disease: The usual daily dose is 500 mg IV once daily in


    concomitant therapy with anticholinergic agent. After concomitant
    therapy with anticholinergic agent for 3-4 weeks, citicoline should be
    discontinued and be considered. Dose of anticholinergic agent may be
    increased or citicoline 250-500 mg may be administered concomitantly
    once daily, every 2-3 weeks unless levodopa can be used. Administration
    of citicoline should be stopped, provided that after administration of
    citicoline 500 mg plus anticholinergic agent everyday for 2 weeks,
    diseases are not improved. It is advisable to avoid concomitant
    administration with levodopa since combination may cause impairment
    of myotonia.

    Pancreatitis: Under concomitant therapy with antiproteolytic agents,


    citicoline 1 g is administered IV once a day for 2 consecutive weeks.

    Or as prescribed by the physician.


    Contraindications Patients with parasympathetic hypertonia.
    Special Precautions In case of stupor caused by acute or severe or progressive head trauma or
    cerebral surgery, it should be given in concomitant with depressant and
    hypothermic agent.

    Use in pregnancy & lactation: Since it has not been established


    whether citicoline may adversely affect pregnant women, citicoline
    should not be used in pregnant women or women of childbearing
    potential unless the benefit of treatment is considered to outweigh the
    risk.

    Use in children: It has not been established whether citicoline may


    adversely affect children.

    Use in elderly: Use in elderly should be taken with caution considering


    manifestation of adverse effects.
    Adverse Drug Shock: Rarely, shock may occur. It should be sufficiently observed if
    Reactions hypotension, compression of chest and dyspnea have developed.
    Administration should be discontinued and/or appropriate therapy be
    instituted.

    Hypersensitivity: Eruption may appear occasionaly, in this case


    administration should be discontinued.

    Psychoneurologic: Headache, vertigo, excitation can develop.

    Gastrointestinal: Occasionally, nausea and rarely anorexia may occur.

    Hepatic: Abnormalities in hepatic test may occur.

    Others: Sometimes, burning sensation, temporary change in blood


    pressure and malaise may appear.
    Click to view ADR Monitoring Website
    Drug Interactions In combination with levodopa, Citilin can increase effects of levodopa.
    View more drug interactions for Citilin
    Storage Store at temperatures not exceeding 30°C.
    Mechanism of Pharmacokinetics: Citicoline is a water-soluble compound with >80%
    Action bioavailability. Pharmacokinetic studies on healthy adults show oral
    doses of citicoline are rapidly absorbed, with <1% excreted in feces.
    Plasma levels peak in a biphasic manner, at 1 hr after ingestion followed
    by a second larger peak at 24 hrs post-dosing. Citicoline is metabolized
    in the gut well and liver. The byproducts of exogenous citicoline formed
    by hydrolysis in the intestinal wall are choline and cytidine. Following
    absorption, choline and cytidine are dispersed throughout the body, enter
    systemic circulation for utilization in various biosynthetic pathways and
    cross the blood-brain barrier for resynthesis into citicoline in the brain.
    MIMS Class Nootropics & Neurotonics
    ATC Classification N06BX06 - Citicoline ; Belongs to the class of other psychostimulants
    and nootropics.
    Poison Schedule Rx
    Presentation/Packing Amp (clear, colorless solution in colorless amp) 500 mg/ 2mL x 10's. 1
    g/4 mL (clear, colorless solution in colorless amp) x 10's

    flunarizine

    MIMS Class : Antimigraine Preparations


    See available brands of flunarizine

    See related flunarizine information

    Indication & Oral


    Dosage Prophylaxis of migraine, Prophylaxis of vertigo and vestibular disorders,
    Prophylaxis of peripheral and cerebrovascular disorders
    Adult: 5-10 mg daily at bedtime.

    Administration May be taken with or without food.

    Contraindications Pregnancy, lactation, GI or urinary tract obstruction, acute porphyrias.

    Special Precautions Driving or operating machinery, epilepsy, elderly, CVS disease, glaucoma.

    Adverse Drug Drowsiness. Rarely wt gain, headache, depression, gastric pain, dry mouth,
    Reactions insomnia, extrapyramidal reactions, galactorrhoea.

    Drug Interactions Plasma levels reduced by phenytoin, carbamazepine, valproic acid.


    Click to view more Drug Interactions
    Storage Oral: Store below 25°C.

    Mechanism of Flunarizine has H1-receptor blocking action and calcium-channel blocking effect. It
    Action has also been used as an adjunct epileptic therapy for patients refractory to
    standard treatment regimens.
    Absorption: Absorbed well from the GI tract (oral).
    Distribution: Highly lipophilic. Protein-binding: >90%.
    Metabolism: Extensive.
    Excretion: Via bile (as metabolites); 18 days (elimination half-life).

    MIMS Class Antimigraine Preparations

    ATC Classification N07CA03 - flunarizine; Belongs to the class of preparations used in the treatment
    of vertigo.

    piracetam

    MIMS Class : Nootropics & Neurotonics


    See available brands of piracetam

    See related piracetam information

    Indication Listed in Dosage.

    Dosage Adult: PO Adjunct in treatment of cortical myoclonus 7.2 g/day in 2-3 divided
    doses, increase if needed. Max: 20 g/day. Cognitive enhancer 2.4 g/day in 2-3
    divided doses. Severe: Up to 4.8 g/day. IV/IM Cognitive enhancer 1-2 g 3
    times/day.
    Click to view Dosage by Indications

    Administration Should be taken with food. (Take before meals.)

    Contraindications Hepatic and severe renal impairment. Cerebral haemorrhage. Pregnancy and
    lactation.

    Special Precautions Avoid abrupt withdrawal. Impaired renal function. Cardiac disorders. Haemostatic
    disorders. Patients who have recently undergone major surgery. Elderly.

    Adverse Drug Hyperkinesia, nervousness, depression, diarrhoea, rashes. CNS stimulation, sleep
    Reactions disturbances, dizziness, excitement, insomnia, somnolence, wt gain.

    Drug Interactions May increase prothrombin time in patients who are on warfarin.
    Click to view more Drug Interactions

    Mechanism of For details of the mechanism of action, pharmacology and pharmacokinetics and
    Action toxicology ... click to view

    MIMS Class Nootropics & Neurotonics

    ATC Classification N06BX03 - piracetam; Belongs to the class of other agents used as CNS stimulant.

    Diabetes Therapy

    Insulin product SciLin receives health care


    registration in the Philippines
    Published in Obesity and Diabetes Week, March 21st, 2005

    The directors of SciGen Limited announced that the company has received health care registration for its
    insulin product SciLin in the Philippines.

    Preparations are well underway for the sales launch of SciLin in the Philippines to occur as soon
    as possible.

    SciLin is a second-generation recombinant human insulin that SciGen has the exclusive rights to
    market in the Asia Pacific Region.

    SciLin is currently registered and sold by SciGen or its partners in India, Vietnam, and Pakistan.

    This article was prepared by Obesity & Diabetes Week editors from staff and other reports.
    Copyright 2005, Obesity & Diabetes...

    You might also like